OasisLMS

1. To register, press the "Log In" or "Register" button.
2. Sign in with your scai.org username and password. If you don't have an account, click “Set Up Your Login.”
3. Once registered, you will see a screen where you can add the webinar to your calendar.

Intravenous (IV) platelet inhibition has become a crucial aspect of managing high-risk patients undergoing percutaneous coronary interventions (PCI) in the ccath lab, particularly for those with acute coronary syndromes (ACS), complex coronary lesions, or high thrombus burden. Join expert faculty to discuss management of patients with large clot burden, high-risk post-operative complications, the role of IVC P2Y12 inhibitors, and real-world case examples which illustrate the clinical impact of recent data.

1. Analyze the clinical presentation and intraprocedural challenges of acute myocardial infarction (AMI) with large thrombus burden, and evaluate the role of intravenous antiplatelet agents in optimizing reperfusion strategies.
2. Evaluate the use of intravenous P2Y12 inhibitors in the perioperative management of patients undergoing PCI who are at high risk for post-operative cardiovascular events.
3. Apply evidence-based strategies to balance ischemic and bleeding risks in the cath lab setting.
4. Discuss real-world cases presentations involving the use of IV P2Y12 Inhibitor therapy.

As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities.

Planning Process 
SCAI activities are developed by the SCAI planners prior to and independent of commercial support. Members of the Education Committee reviewed and approved this activity. If planners had relevant financial relationships, the agenda was peer reviewed by a member with no relevant financial relationships.

Mitigation of Relevant Financial Relationships
All participating planners, reviewers, faculty, and staff are required to disclose to SCAI all financial relationships with ineligible companies. SCAI identifies relevant financial relationships and mitigates them before the activity begins. 

Content Validation Statement
SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations.

All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. SCAI does not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of accredited continuing education or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients.

All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis. 

SCAI actively promotes improvements in health care and NOT proprietary interests of an ineligible company. SCAI's educational content is free of marketing or sales of products or services.

Faculty will not actively promote or sell products or services that serve their personal professional or financial interests during accredited education. 

SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration (FDA), at first mention and where appropriate in the content.